PRESS RELEASE published on 02/07/2024 at 07:45, 2 years 6 months ago Marinomed Biotech AG with important progress for Carragelose in 2024 Marinomed Biotech AG enrolls first patient in clinical study for Carragelose eye drops and receives patents in Singapore, South Korea, and Brazil, strengthening its IP portfolio. The company plans to launch Carragelose eye drops and nasal spray in 2024, targeting allergy and eye care markets Clinical Study Marinomed Biotech AG Carragelose Patents Allergy And Eye Care Markets
PRESS RELEASE published on 10/17/2023 at 07:45, 2 years 10 months ago Marinomed Biotech AG resumes Nice & Green Convertible Notes Funding Program with reduced volume
PRESS RELEASE published on 08/17/2023 at 07:45, 3 years ago Marinomed Biotech AG reports record revenues in the first half of the year and pushes business development activities
PRESS RELEASE published on 08/09/2023 at 07:45, 3 years ago Marinomed enters first long-term Solv4U partnership with Shanghaibased SPH Sine Pharmaceutical Laboratories Co. Ltd.
PRESS RELEASE published on 07/27/2023 at 07:45, 3 years 1 month ago Marinomed Biotech AG: M8 Pharmaceuticals obtains market authorization for Carragelose nasal spray in Mexico
PRESS RELEASE published on 07/13/2023 at 07:45, 3 years 1 month ago Peer-reviewed publication by Marinomed Biotech AG and Friedrich-Alexander-University Erlangen-Nürnberg reconfirms broad virus-blocking effectiveness of iota-carrageenan
PRESS RELEASE published on 06/21/2023 at 17:00, 3 years 2 months ago Marinomed Biotech AG: Annual General Meeting elects Dr. Eva Hofstädter-Thalmann as a new member of the Supervisory Board
PRESS RELEASE published on 06/15/2023 at 07:45, 3 years 2 months ago Marinomed Biotech AG prepares launch of Carragelose eye drops in 2024
PRESS RELEASE published on 05/23/2023 at 07:45, 3 years 3 months ago Marinomed Biotech AG reports best first quarter in company history
PRESS RELEASE published on 04/19/2023 at 07:45, 3 years 4 months ago Marinomed Biotech AG with Carragelose record sales in 2022 and positive outlook for 2023
Published on 09/01/2026 at 10:00, 1 hour 6 minutes ago Eagle Plains' Partner Xcite Uranium Commences Drill Program at the Lorado Uranium Project, Saskatchewan
Published on 09/01/2026 at 01:39, 9 hours 27 minutes ago GLG Life Tech Corporation Reports 2026 Second Quarter Financial Results
Published on 09/01/2026 at 01:00, 10 hours 6 minutes ago Lobe Sciences Ltd. Announces Closing of Upsize to Non-Brokered Private Placement
Published on 08/31/2026 at 23:30, 11 hours 36 minutes ago Datametrex Announces Annual and Special Meeting Voting Results
Published on 08/31/2026 at 23:00, 12 hours 6 minutes ago Silver Storm Closes Second and Final Tranche of Non-Brokered Private Placement for Aggregate Gross Proceeds of $21.0 Million
Published on 09/01/2026 at 10:45, 21 minutes ago Cloover reaches profitability at $350M run-rate as it launches AI-native neo-utility
Published on 09/01/2026 at 10:05, 1 hour 1 minute ago Dublin-born composer silenced by the Nazis returns to Vienna's Musikverein
Published on 09/01/2026 at 10:05, 1 hour 1 minute ago THE SOFTEST EXPRESSION OF HUBLOT'S MATERIAL MASTERY
Published on 09/01/2026 at 09:40, 1 hour 25 minutes ago KUKA Global Executives Visit Centron for Technical Exchange on Intelligent Assembly Manufacturing
Published on 09/01/2026 at 09:33, 1 hour 32 minutes ago High-Grade Titanium in Australia: New Exception Drill Results from Surface!
Published on 08/31/2026 at 18:00, 17 hours 6 minutes ago MISE A DISPOSITION RAPPORT FINANCIER ANNUEL 2025/2026
Published on 08/31/2026 at 17:45, 17 hours 21 minutes ago Disclosure of transactions in own shares from August 24 to August 28, 2026
Published on 08/31/2026 at 17:45, 17 hours 21 minutes ago Déclaration hebdomadaire d'opérations effectuées du 24 au 28 août 2026
Published on 08/31/2026 at 17:45, 17 hours 21 minutes ago Déclaration hebdomadaire de rachat d'actions
